Bipolar Disorder, Concentration Ability Impaired, Lithium - Induced Nephropathy, Lithium Toxicities, Nephrogenic Diabetes Insipidus
Conditions
Brief summary
Lithium therapy is cornerstone in therapy of bipolar disorders. A well known side-effect of lithium therapy is a urinary concentration defect which manifests in it's most severe form as nephrogenic diabetes insipidus. The development of urinary concentration defects and its progression to nephrogenic diabetes insipidus in the population of lithium treated patients is unknown and therefore this study aims to evaluate the decline of urinary concentration defects in a Dutch population of lithium treated patients. In this prospective cohort study, 51 participants treated with lithium at Canisius Wilhelmina Hospital, Nijmegen and included in the previous study in 2012 will be approached to undergo a follow-up dDAVP-test.
Interventions
DIAGNOSTIC_TESTDeamino Arginine Vasopressin (dDAVP)
After voiding, 40 μg 1-desamino-8-D arginine vasopressin (dDAVP) will be administered intranasally. Throughout the day, urine volume and maximal renal concentrating ability will be determined by measuring osmolality in urine collected at 4 and 6 hours after administration of dDAVP. In addition, water intake, body weight, blood pressure and heart rate will be determined at baseline and 6 hours after administration of dDAVP.
Sponsors
Radboud University Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* included in the previous study * men and women * age ≥ 18 years
Exclusion criteria
* General contra-indications for participation in a trial: * inability to give informed consent * pregnancy * unstable psychiatric condition * Alternative causes of (nephrogenic) diabetes insipidus: * hypokalemia (plasma potassium \< 3.0 mmol/l) * severe hypercalcemia (albumin-corrected plasma calcium \> 2.80 mmol/l) * hyperglycemia (plasma glucose \> 10.0 mmol/l) * history of amyloidosis, Sjögren's syndrome or Sickle cell anemia * previous treatment with ifosfamide * established primary polydipsia or central diabetes insipidus * Contra-indications for dDAVP administration: * inability to comply with water restriction * renal insufficiency (GFR \< 45 ml/min/1.73 m2) * hyponatremia (plasma sodium \< 130 mmol/l) * instable angina pectoris * decompensated cardial insufficiency * Other: * concomitant treatment with desmopressin or democlocycline
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Decline renal concentration ability | 10 years | To explore the decline in renal concentration ability (RCA) in a Dutch population of lithium treated patient. The primary endpoint is the percentual change in maximal urine osmolality. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Relation between changes in kidney function and renal concentration ability | 10 years | To determine the correlation between changes in kidney function and renal concentration ability |
| Relation between history of lithium-use and renal concentration ability | 10 years | To determine the relationship between renal concentration ability and clinical parameters (duration of lithium therapy, plasma lithium concentration, baseline plasma creatinine, sodium and potassium concentration and baseline urinary osmolality) of lithium treated patients. |
| Chronic kidney disease | 10 years | To determine the number of patients with chronic kidney disease at follow-up. |
| Decline in kidney-function | 10 years | To explore the decline in kidneyfunction (expressed as eGFR, estimated by the CKD-EPI equation). |
Countries
Netherlands
Contacts
Primary ContactM.J. van der Aa
Outcome results
None listed